HK1256137A1 - 用於治療惡性實體腫瘤的減毒細菌 - Google Patents

用於治療惡性實體腫瘤的減毒細菌

Info

Publication number
HK1256137A1
HK1256137A1 HK18115218.4A HK18115218A HK1256137A1 HK 1256137 A1 HK1256137 A1 HK 1256137A1 HK 18115218 A HK18115218 A HK 18115218A HK 1256137 A1 HK1256137 A1 HK 1256137A1
Authority
HK
Hong Kong
Prior art keywords
treatment
solid tumors
attenuated bacteria
malignant solid
virulence attenuated
Prior art date
Application number
HK18115218.4A
Other languages
English (en)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Guy R Cornelis
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of HK1256137A1 publication Critical patent/HK1256137A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0291Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18115218.4A 2015-11-19 2018-11-28 用於治療惡性實體腫瘤的減毒細菌 HK1256137A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195490 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (1)

Publication Number Publication Date
HK1256137A1 true HK1256137A1 (zh) 2019-09-13

Family

ID=54697464

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115218.4A HK1256137A1 (zh) 2015-11-19 2018-11-28 用於治療惡性實體腫瘤的減毒細菌

Country Status (24)

Country Link
US (1) US11166987B2 (zh)
EP (2) EP3377094B1 (zh)
JP (1) JP7060503B2 (zh)
KR (1) KR20180081583A (zh)
CN (1) CN108472348B (zh)
AU (1) AU2016358257B2 (zh)
BR (2) BR122023024697A2 (zh)
CA (1) CA3003563A1 (zh)
CY (1) CY1124564T1 (zh)
DK (1) DK3377094T3 (zh)
EA (1) EA201890868A1 (zh)
ES (1) ES2880431T3 (zh)
HK (1) HK1256137A1 (zh)
HR (1) HRP20211191T1 (zh)
HU (1) HUE055132T2 (zh)
IL (1) IL259052B2 (zh)
LT (1) LT3377094T (zh)
PL (1) PL3377094T3 (zh)
PT (1) PT3377094T (zh)
RS (1) RS62152B1 (zh)
SG (1) SG11201803643TA (zh)
SI (1) SI3377094T1 (zh)
WO (1) WO2017085233A1 (zh)
ZA (1) ZA201803902B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948570C (en) 2014-05-21 2023-09-12 Universitaet Basel Bacteria-based protein delivery
US11702663B2 (en) 2015-11-19 2023-07-18 Universität Basel Bacteria-based protein delivery
EP3957645A1 (en) 2016-12-20 2022-02-23 Universität Basel Virulence attenuated bacteria based protein delivery
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
IL302334A (en) * 2020-10-27 2023-06-01 T3 Pharmaceuticals Ag Providing bacteria-based protein
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US6596509B1 (en) 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
AU2001294834A1 (en) 2000-09-26 2002-04-08 Beth Israel Deaconess Medical Center Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002312778A1 (en) 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
WO2007044406A2 (en) 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2268313A2 (en) 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
US10709784B2 (en) 2011-06-08 2020-07-14 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−4受容体結合融合タンパク質及びその使用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CA2948570C (en) 2014-05-21 2023-09-12 Universitaet Basel Bacteria-based protein delivery
US11702663B2 (en) 2015-11-19 2023-07-18 Universität Basel Bacteria-based protein delivery
EP3957645A1 (en) 2016-12-20 2022-02-23 Universität Basel Virulence attenuated bacteria based protein delivery

Also Published As

Publication number Publication date
SI3377094T1 (sl) 2021-09-30
BR112018009753A8 (pt) 2019-02-26
JP7060503B2 (ja) 2022-04-26
JP2019500026A (ja) 2019-01-10
EA201890868A1 (ru) 2018-12-28
WO2017085233A1 (en) 2017-05-26
AU2016358257A1 (en) 2018-05-10
LT3377094T (lt) 2021-08-10
IL259052B1 (en) 2023-11-01
EP3903813A1 (en) 2021-11-03
AU2016358257B2 (en) 2023-08-17
BR122023024697A2 (pt) 2023-12-26
HUE055132T2 (hu) 2021-11-29
ES2880431T3 (es) 2021-11-24
HRP20211191T1 (hr) 2021-10-29
EP3377094B1 (en) 2021-04-28
BR112018009753B1 (pt) 2024-02-20
IL259052B2 (en) 2024-03-01
EP3377094A1 (en) 2018-09-26
DK3377094T3 (da) 2021-08-02
CY1124564T1 (el) 2022-07-22
RS62152B1 (sr) 2021-08-31
CN108472348B (zh) 2022-12-27
ZA201803902B (en) 2019-03-27
US20190015497A1 (en) 2019-01-17
PT3377094T (pt) 2021-07-08
BR112018009753A2 (pt) 2018-11-13
PL3377094T3 (pl) 2021-12-13
KR20180081583A (ko) 2018-07-16
CN108472348A (zh) 2018-08-31
IL259052A (en) 2018-07-31
US11166987B2 (en) 2021-11-09
SG11201803643TA (en) 2018-06-28
CA3003563A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
HK1247202A1 (zh) 用於治療癌症的化合物
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
HRP20190580T1 (hr) Kombinirana terapija radi liječenja rezistentnih bakterijskih infekcija
HK1256137A1 (zh) 用於治療惡性實體腫瘤的減毒細菌
IL285077A (en) Compounds for the treatment of cancer
RS61536B1 (sr) Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
IL259996A (en) Combinations for cancer treatment
SG10201801562PA (en) Combination method for treatment of cancer
HK1247931A1 (zh) 用於診斷和治療癌症的組合物和方法
EP3134436A4 (en) Treatment of h-ras-driven tumors
HK1251009B (zh) 用於治療癌症的治療組合物
HK1250949A1 (zh) 使用由減毒細菌遞送的回憶抗原治療癌症
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
GB201408297D0 (en) Treatment of cancer
ZA201707024B (en) Cancer treatment composition
IL255167A0 (en) Compounds for the treatment of cancer
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
EP3125878A4 (en) Methods of treating breast cancer
GB201417456D0 (en) Treatment of cancer
HK1259029A1 (zh) 用於治療癌症的具有抗趨除特性的組合物
ZA201704589B (en) Compounds for the treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201409362D0 (en) Treatment of cancer